Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever
Objective Familial Mediterranean fever (FMF) is characterised by recurrent periodic febrile attacks and persistent subclinical inflammation. The damage-associated molecular pattern (DAMP) protein S100A12 has proven to be a sensitive marker for disease activity and inflammation in numerous inflammato...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2010-04, Vol.69 (4), p.677-682 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 682 |
|---|---|
| container_issue | 4 |
| container_start_page | 677 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 69 |
| creator | Kallinich, Tilmann Wittkowski, Helmut Keitzer, Rolf Roth, Johannes Foell, Dirk |
| description | Objective Familial Mediterranean fever (FMF) is characterised by recurrent periodic febrile attacks and persistent subclinical inflammation. The damage-associated molecular pattern (DAMP) protein S100A12 has proven to be a sensitive marker for disease activity and inflammation in numerous inflammatory disorders. The aim of this study was to analyse the role of S100A12 in the detection of inflammation in patients with FMF. Methods 52 children and adolescents with a clinical and/or genetic diagnosis of FMF were prospectively followed-up over 18 months (in total 196 visits). During clinical visits, erythrocyte sedimentation rate, C reactive protein, serum amyloid A and S100A12 serum concentrations were determined. Patients were categorised into four groups according to the clinical activity of FMF. Results Serum concentrations of S100A12 were excessively increased in patients with a mean increase of about 290-fold in active FMF above normal controls. S100A12 decreased significantly after introduction of colchicine therapy. Serum concentrations of S100A12 were significantly higher in patients treated with colchicine with persistent symptoms (mean±SEM, 6260±2120 ng/ml) than in those with clinically controlled disease (440±80 ng/ml, p |
| doi_str_mv | 10.1136/ard.2009.114363 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733782037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733782037</sourcerecordid><originalsourceid>FETCH-LOGICAL-b427t-89d29eef815df29f197a06686d15ac898c4fed0067f99ea4b4215ac0a6c26f873</originalsourceid><addsrcrecordid>eNqFkE2LFDEQhoMo7uzq2Zs0iAhC7-ajOx_HZdBVmR0P6t4kZDoVzJjuzCbdg_570_SwghdPoVJPVb08CL0g-JIQxq9MspcUY1WqhnH2CK1Iw2VNMceP0QpjzOpGcXGGznPelxJLIp-iM6IEp4w3K_R9C9OY4uGHD7WF5I9gqy8E42tCK5OrIR4hVDsfe5N-Qqqiq_zggul7M_o4lKJypvfBm1DdgvUjpGQGMOUbjpCeoSfOhAzPT-8F-vb-3df1h3rz-ebj-npT7xoqxloqSxWAk6S1jipX4hnMueSWtKaTSnaNA4sxF04pME2ZmhvY8I5yJwW7QG-WvYcU7yfIo-597iCEkiVOWQvGhKSYzeSrf8h9nNJQwmkihJCtEgoX6mqhuhRzTuD0Ifmi4LcmWM_idRGvZ_F6EV8mXp72Trse7F_-ZLoAr0-AyZ0JrmjqfH7gKG0VpUoWrl44n0f49dAv-jUXTLR6e7fW69stu2ObT3o-_Hbhd_3-vyn_AOV9pkY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777859790</pqid></control><display><type>article</type><title>Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Kallinich, Tilmann ; Wittkowski, Helmut ; Keitzer, Rolf ; Roth, Johannes ; Foell, Dirk</creator><creatorcontrib>Kallinich, Tilmann ; Wittkowski, Helmut ; Keitzer, Rolf ; Roth, Johannes ; Foell, Dirk</creatorcontrib><description>Objective Familial Mediterranean fever (FMF) is characterised by recurrent periodic febrile attacks and persistent subclinical inflammation. The damage-associated molecular pattern (DAMP) protein S100A12 has proven to be a sensitive marker for disease activity and inflammation in numerous inflammatory disorders. The aim of this study was to analyse the role of S100A12 in the detection of inflammation in patients with FMF. Methods 52 children and adolescents with a clinical and/or genetic diagnosis of FMF were prospectively followed-up over 18 months (in total 196 visits). During clinical visits, erythrocyte sedimentation rate, C reactive protein, serum amyloid A and S100A12 serum concentrations were determined. Patients were categorised into four groups according to the clinical activity of FMF. Results Serum concentrations of S100A12 were excessively increased in patients with a mean increase of about 290-fold in active FMF above normal controls. S100A12 decreased significantly after introduction of colchicine therapy. Serum concentrations of S100A12 were significantly higher in patients treated with colchicine with persistent symptoms (mean±SEM, 6260±2120 ng/ml) than in those with clinically controlled disease (440±80 ng/ml, p<0.001). In contrast to classical markers of inflammation, S100A12 was significantly elevated in clinically unaffected homozygous MEFV gene mutation carriers, indicating subclinical inflammation. Conclusions S100A12 is a valuable biomarker for monitoring disease activity, inflammation and response to colchicine treatment in patients with FMF. It might even be more sensitive in detecting subclinical inflammation than other available indicators.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.2009.114363</identifier><identifier>PMID: 19762364</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Adolescent ; Biological and medical sciences ; Biomarkers - blood ; Blood Sedimentation ; C-Reactive Protein - analysis ; Child ; Child, Preschool ; Colchicine - therapeutic use ; Cytokines ; Cytoskeletal Proteins - genetics ; Disease ; Diseases of the osteoarticular system ; Familial Mediterranean Fever - diagnosis ; Familial Mediterranean Fever - drug therapy ; Familial Mediterranean Fever - genetics ; Female ; Follow-Up Studies ; Granulocytes ; Humans ; Inflammation ; Inflammation - diagnosis ; Inflammation - drug therapy ; Inflammation - genetics ; Inflammatory diseases ; Inflammatory joint diseases ; Laboratories ; Male ; Malformations and congenital and or hereditary diseases involving bones. Joint deformations ; Medical sciences ; Mutation ; Neutrophils ; Prospective Studies ; Proteins ; Pyrin ; S100 Proteins - blood ; S100A12 Protein ; Serum Amyloid A Protein - analysis ; Studies ; Treatment Outcome ; Young Adult</subject><ispartof>Annals of the rheumatic diseases, 2010-04, Vol.69 (4), p.677-682</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2010 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b427t-89d29eef815df29f197a06686d15ac898c4fed0067f99ea4b4215ac0a6c26f873</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/69/4/677.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/69/4/677.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77600,77631</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22592298$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19762364$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kallinich, Tilmann</creatorcontrib><creatorcontrib>Wittkowski, Helmut</creatorcontrib><creatorcontrib>Keitzer, Rolf</creatorcontrib><creatorcontrib>Roth, Johannes</creatorcontrib><creatorcontrib>Foell, Dirk</creatorcontrib><title>Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objective Familial Mediterranean fever (FMF) is characterised by recurrent periodic febrile attacks and persistent subclinical inflammation. The damage-associated molecular pattern (DAMP) protein S100A12 has proven to be a sensitive marker for disease activity and inflammation in numerous inflammatory disorders. The aim of this study was to analyse the role of S100A12 in the detection of inflammation in patients with FMF. Methods 52 children and adolescents with a clinical and/or genetic diagnosis of FMF were prospectively followed-up over 18 months (in total 196 visits). During clinical visits, erythrocyte sedimentation rate, C reactive protein, serum amyloid A and S100A12 serum concentrations were determined. Patients were categorised into four groups according to the clinical activity of FMF. Results Serum concentrations of S100A12 were excessively increased in patients with a mean increase of about 290-fold in active FMF above normal controls. S100A12 decreased significantly after introduction of colchicine therapy. Serum concentrations of S100A12 were significantly higher in patients treated with colchicine with persistent symptoms (mean±SEM, 6260±2120 ng/ml) than in those with clinically controlled disease (440±80 ng/ml, p<0.001). In contrast to classical markers of inflammation, S100A12 was significantly elevated in clinically unaffected homozygous MEFV gene mutation carriers, indicating subclinical inflammation. Conclusions S100A12 is a valuable biomarker for monitoring disease activity, inflammation and response to colchicine treatment in patients with FMF. It might even be more sensitive in detecting subclinical inflammation than other available indicators.</description><subject>Adolescent</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Blood Sedimentation</subject><subject>C-Reactive Protein - analysis</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Colchicine - therapeutic use</subject><subject>Cytokines</subject><subject>Cytoskeletal Proteins - genetics</subject><subject>Disease</subject><subject>Diseases of the osteoarticular system</subject><subject>Familial Mediterranean Fever - diagnosis</subject><subject>Familial Mediterranean Fever - drug therapy</subject><subject>Familial Mediterranean Fever - genetics</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Granulocytes</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - diagnosis</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - genetics</subject><subject>Inflammatory diseases</subject><subject>Inflammatory joint diseases</subject><subject>Laboratories</subject><subject>Male</subject><subject>Malformations and congenital and or hereditary diseases involving bones. Joint deformations</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>Neutrophils</subject><subject>Prospective Studies</subject><subject>Proteins</subject><subject>Pyrin</subject><subject>S100 Proteins - blood</subject><subject>S100A12 Protein</subject><subject>Serum Amyloid A Protein - analysis</subject><subject>Studies</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkE2LFDEQhoMo7uzq2Zs0iAhC7-ajOx_HZdBVmR0P6t4kZDoVzJjuzCbdg_570_SwghdPoVJPVb08CL0g-JIQxq9MspcUY1WqhnH2CK1Iw2VNMceP0QpjzOpGcXGGznPelxJLIp-iM6IEp4w3K_R9C9OY4uGHD7WF5I9gqy8E42tCK5OrIR4hVDsfe5N-Qqqiq_zggul7M_o4lKJypvfBm1DdgvUjpGQGMOUbjpCeoSfOhAzPT-8F-vb-3df1h3rz-ebj-npT7xoqxloqSxWAk6S1jipX4hnMueSWtKaTSnaNA4sxF04pME2ZmhvY8I5yJwW7QG-WvYcU7yfIo-597iCEkiVOWQvGhKSYzeSrf8h9nNJQwmkihJCtEgoX6mqhuhRzTuD0Ifmi4LcmWM_idRGvZ_F6EV8mXp72Trse7F_-ZLoAr0-AyZ0JrmjqfH7gKG0VpUoWrl44n0f49dAv-jUXTLR6e7fW69stu2ObT3o-_Hbhd_3-vyn_AOV9pkY</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Kallinich, Tilmann</creator><creator>Wittkowski, Helmut</creator><creator>Keitzer, Rolf</creator><creator>Roth, Johannes</creator><creator>Foell, Dirk</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20100401</creationdate><title>Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever</title><author>Kallinich, Tilmann ; Wittkowski, Helmut ; Keitzer, Rolf ; Roth, Johannes ; Foell, Dirk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b427t-89d29eef815df29f197a06686d15ac898c4fed0067f99ea4b4215ac0a6c26f873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Blood Sedimentation</topic><topic>C-Reactive Protein - analysis</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Colchicine - therapeutic use</topic><topic>Cytokines</topic><topic>Cytoskeletal Proteins - genetics</topic><topic>Disease</topic><topic>Diseases of the osteoarticular system</topic><topic>Familial Mediterranean Fever - diagnosis</topic><topic>Familial Mediterranean Fever - drug therapy</topic><topic>Familial Mediterranean Fever - genetics</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Granulocytes</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - diagnosis</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - genetics</topic><topic>Inflammatory diseases</topic><topic>Inflammatory joint diseases</topic><topic>Laboratories</topic><topic>Male</topic><topic>Malformations and congenital and or hereditary diseases involving bones. Joint deformations</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>Neutrophils</topic><topic>Prospective Studies</topic><topic>Proteins</topic><topic>Pyrin</topic><topic>S100 Proteins - blood</topic><topic>S100A12 Protein</topic><topic>Serum Amyloid A Protein - analysis</topic><topic>Studies</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kallinich, Tilmann</creatorcontrib><creatorcontrib>Wittkowski, Helmut</creatorcontrib><creatorcontrib>Keitzer, Rolf</creatorcontrib><creatorcontrib>Roth, Johannes</creatorcontrib><creatorcontrib>Foell, Dirk</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kallinich, Tilmann</au><au>Wittkowski, Helmut</au><au>Keitzer, Rolf</au><au>Roth, Johannes</au><au>Foell, Dirk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>69</volume><issue>4</issue><spage>677</spage><epage>682</epage><pages>677-682</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objective Familial Mediterranean fever (FMF) is characterised by recurrent periodic febrile attacks and persistent subclinical inflammation. The damage-associated molecular pattern (DAMP) protein S100A12 has proven to be a sensitive marker for disease activity and inflammation in numerous inflammatory disorders. The aim of this study was to analyse the role of S100A12 in the detection of inflammation in patients with FMF. Methods 52 children and adolescents with a clinical and/or genetic diagnosis of FMF were prospectively followed-up over 18 months (in total 196 visits). During clinical visits, erythrocyte sedimentation rate, C reactive protein, serum amyloid A and S100A12 serum concentrations were determined. Patients were categorised into four groups according to the clinical activity of FMF. Results Serum concentrations of S100A12 were excessively increased in patients with a mean increase of about 290-fold in active FMF above normal controls. S100A12 decreased significantly after introduction of colchicine therapy. Serum concentrations of S100A12 were significantly higher in patients treated with colchicine with persistent symptoms (mean±SEM, 6260±2120 ng/ml) than in those with clinically controlled disease (440±80 ng/ml, p<0.001). In contrast to classical markers of inflammation, S100A12 was significantly elevated in clinically unaffected homozygous MEFV gene mutation carriers, indicating subclinical inflammation. Conclusions S100A12 is a valuable biomarker for monitoring disease activity, inflammation and response to colchicine treatment in patients with FMF. It might even be more sensitive in detecting subclinical inflammation than other available indicators.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>19762364</pmid><doi>10.1136/ard.2009.114363</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2010-04, Vol.69 (4), p.677-682 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733782037 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Adolescent Biological and medical sciences Biomarkers - blood Blood Sedimentation C-Reactive Protein - analysis Child Child, Preschool Colchicine - therapeutic use Cytokines Cytoskeletal Proteins - genetics Disease Diseases of the osteoarticular system Familial Mediterranean Fever - diagnosis Familial Mediterranean Fever - drug therapy Familial Mediterranean Fever - genetics Female Follow-Up Studies Granulocytes Humans Inflammation Inflammation - diagnosis Inflammation - drug therapy Inflammation - genetics Inflammatory diseases Inflammatory joint diseases Laboratories Male Malformations and congenital and or hereditary diseases involving bones. Joint deformations Medical sciences Mutation Neutrophils Prospective Studies Proteins Pyrin S100 Proteins - blood S100A12 Protein Serum Amyloid A Protein - analysis Studies Treatment Outcome Young Adult |
| title | Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A09%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutrophil-derived%20S100A12%20as%20novel%20biomarker%20of%20inflammation%20in%20familial%20Mediterranean%20fever&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Kallinich,%20Tilmann&rft.date=2010-04-01&rft.volume=69&rft.issue=4&rft.spage=677&rft.epage=682&rft.pages=677-682&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.2009.114363&rft_dat=%3Cproquest_cross%3E733782037%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777859790&rft_id=info:pmid/19762364&rfr_iscdi=true |